Patents by Inventor Brad Sherborne
Brad Sherborne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8084457Abstract: The present invention relates to 4,6-disubstituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, and pharmaceutical compositions containing at least one of said 4,6-di substituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof.Type: GrantFiled: September 15, 2004Date of Patent: December 27, 2011Assignees: Lead Discovery Center GmbH, Bayer Pharma AGInventors: Axel Choidas, Alexander Backes, Matt Cotten, Ola Engkvist, Beatrice Felber, Achim Freisleben, Klaus Godl, Zoltán Greff, Peter Habenberger, Doris Hafenbradl, Christian Hartung, Thomas Herget, Edmund Hoppe, Bert Klebl, Andrea Missio, Gerhard Müller, Wilfried Schwab, Birgit Zech, Jose Bravo, John Harris, Joelle Le, Jackie Macritchie, Vladimir Savic, Brad Sherborne, Don Simpson
-
Patent number: 8022076Abstract: This invention relates to novel compound of formula (I) or pharmaceutically acceptable salts thereof. The invention is also directed to the uses of compounds having formula (I) in the treatment or prevention of diseases or disorders which requires potassium channel inhibition to an animal, mammal or human in need thereof. The invention is also directed to the use of compounds having formula (I) in the treatment or prevention of arrhythmia to an animal, mammal or human in need thereof.Type: GrantFiled: June 10, 2004Date of Patent: September 20, 2011Assignee: Xention LimitedInventors: John Ford, Nicholas John Palmer, John Frederick Atherall, David John Madge, Brad Sherborne, Mark Bushfield, Edward Benedict Stevens
-
Patent number: 7960365Abstract: The invention provides for compounds having the structure according to the formula I wherein: X is a carbon or nitrogen atom; Ar is phenyl or heteroaromatic ring; R1 is hydrogen, halogen, CN or (1C-4C)alkyl; R2 is hydrogen, halogen or optionally fluorinated (1C-3C)alkoxy; R3 and R5 are independently hydrogen, optionally halogenated (1C-4C)alkyl, optionally halogenated (1C-4C)alkoxy, optionally halogenated aryl(1C-4C)alkoxy, optionally halogenated (1C-4C)alkenyl or hydroxylmethyl; R4 is hydrogen, halogen, optionally halogenated (1C-4C)alkoxy or optionally halogenated aryl(1C-4C)alkoxy; R6 is hydrogen, benzyl, optionally substituted with one or more halogens or (1C-4C)alkyl, or R6 is optionally halogenated (1C-4C)alkyl; each R7 independently is hydrogen, halogen, optionally halogenated (1C-4C)alkyl or optionally halogenated (1C-4C)alkoxy and pharmaceutically suitable acid addition salts thereof for use as glucocorticoid receptor modulators, in particular for treatment of central nervous system disorders.Type: GrantFiled: December 19, 2006Date of Patent: June 14, 2011Assignee: N.V. OrganonInventors: Niall Morton Hamilton, Simon James Anthony Grove, Michael John Kiczun, John Richard Morphy, Brad Sherborne, Peter Thomas Albert Littlewood, Angus Richard Brown, Celia Kingsbury, Michael Ohhlmeyer, Koc-Kan Ho, Steven G. Kultgen
-
Patent number: 7893088Abstract: The present invention relates to 6-substituted isoquinoline derivatives having the general Formula I wherein X is O, S or NH; Y is OH or NH2; m is 0, 1 or 2; n is 0 or 1; o is 0 or 1; R1 is H, when Y is NH2; or R1 is H, (C1-4)alkyl or halogen, when Y is OH; R2 and R3 are independently H, (C1-4)alkyl or halogen; R4 is H or (C1-6)alkyl, optionally substituted with halogen, (C3-7)cycloalkyl, (C6-10)aryl or a saturated 5- or 6-membered heterocyclic ring comprising 1-3 heteroatoms independently selected from O, S and N, the (C6-10)aryl and heterocyclic ring being optionally substituted with (C1-4)alkyl, (C1-4)alkyloxy or halogen; R5 is H or (C1-4)alkyl; or a pharmaceutically acceptable salt thereof, with the proviso that the compounds of Formula I wherein X is O, Y is OH , n is 0 and m+o=2 are excluded, to pharmaceutical compositions comprising the same, as well as to the use of said 6-substituted isoquinoline derivatives for the preparation of a medicament for the treatment of ROCK-I related disorders such asType: GrantFiled: August 16, 2007Date of Patent: February 22, 2011Assignee: N.V. OrganonInventors: Peter Christopher Ray, Steven Laats, John Richard Morphy, Brad Sherborne
-
Publication number: 20080045566Abstract: The present invention relates to 6-substituted isoquinoline derivatives having the general Formula I wherein X is O, S or NH; Y is OH or NH2; m is 0, 1 or 2; n is 0 or 1; o is 0 or 1; R1 is H, when Y is NH2; or R1 is H, (C1-4)alkyl or halogen, when Y is OH; R2 and R3 are independently H, (C1-4)alkyl or halogen; R4 is H or (C1-6)alkyl, optionally substituted with halogen, (C3-7)cycloalkyl, (C6-10)aryl or a saturated 5- or 6-membered heterocyclic ring comprising 1-3 heteroatoms independently selected from O, S and N, the (C6-10)aryl and heterocyclic ring being optionally substituted with (C1-4)alkyl, (C1-4)alkyloxy or halogen; R5 is H or (C1-4)alkyl; or a pharmaceutically acceptable salt thereof, with the proviso that the compounds of Formula I wherein X is O, Y is OH , n is 0 and m+o=2 are excluded, to pharmaceutical compositions comprising the same, as well as to the use of said 6-substituted isoquinoline derivatives for the preparation of a medicament for the treatment of ROCK-I related disorders such asType: ApplicationFiled: August 16, 2007Publication date: February 21, 2008Applicant: N.V. OrganonInventors: Peter Christopher Ray, Steven Laats, John Richard Morphy, Brad Sherborne
-
Publication number: 20070191344Abstract: The present invention relates to 4,6-disubstituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, and pharmaceutical compositions containing at least one of said 4,6-di substituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: September 15, 2004Publication date: August 16, 2007Inventors: Axel Choidas, Alexander Backes, Matt Cotten, Ola Engkvist, Beatrice Felber, Achim Freisleben, Klaus Godl, Zoltan Greff, Peter Habenberger, Doris Hafenbradl, Christian Hartung, Thomas Herget, Edmund Hoppe, Bert Klebl, Andrea Missio, Gerhard Muller, Wilfried Schwab, Birgit Zech, Jose Bravo, John Harris, Joelle Le, Jackie Macritchie, Vladimir Savic, Brad Sherborne, Don Simpson
-
Publication number: 20070149577Abstract: The invention provides for compounds having the structure according to the formula I wherein: X is a carbon or nitrogen atom; Ar is phenyl or heteroaromatic ring; R1 is hydrogen, halogen, CN or (1C-4C)alkyl; R2 is hydrogen, halogen or optionally fluorinated (1C-3C)alkoxy; R3 and R5 are independently hydrogen, optionally halogenated (1C-4C)alkyl, optionally halogenated (1C-4C)alkoxy, optionally halogenated aryl(1C-4C)alkoxy, optionally halogenated (1C-4C)alkenyl or hydroxylmethyl; R4 is hydrogen, halogen, optionally halogenated (1C-4C)alkoxy or optionally halogenated aryl(1C-4C)alkoxy; R6 is hydrogen, benzyl, optionally substituted with one or more halogens or (1C-4C)alkyl, or R6 is optionally halogenated (1C-4C)alkyl; each R7 independently is hydrogen, halogen, optionally halogenated (1C-4C)alkyl or optionally halogenated (1C-4C)alkoxy and pharmaceutically suitable acid addition salts thereof for use as glucocorticoid receptor modulators, in particular for treatment of central nervous system disorders.Type: ApplicationFiled: December 19, 2006Publication date: June 28, 2007Applicants: N.V. Organon, Pharmacopeia Drug Discovery Inc.Inventors: Niall Hamilton, Simon Grove, Michael Kiczun, John Morphy, Brad Sherborne, Peter Littlewood, Angus Brown, Celia Kingsbury, Michael Ohlmeyer, Koc-Kan Ho, Steven Kultgen
-
Publication number: 20050026935Abstract: This invention relates to novel compound of formula (I) or pharmaceutically acceptable salts thereof. The invention is also directed to the uses of compounds having formula (I) in the treatment or prevention of diseases or disorders which requires potassium channel inhibition to an animal, mammal or human in need thereof. The invention is also directed to the use of compounds having formula (I) in the treatment or prevention of arrhythmia to an animal, mammal or human in need thereof.Type: ApplicationFiled: June 10, 2004Publication date: February 3, 2005Inventors: John Ford, Nicholas Palmer, John Atherall, David Madge, Brad Sherborne, Mark Bushfield, Edward Stevens